M032

AXP000086.1 · Oncolytic virus

Platform
HSV-1 (strain F, gamma34.5-deleted)
Originator
University of Alabama at Birmingham
Sponsor
University of Alabama at Birmingham

Names

NameTypeSource
M032preferred name, codecurator, ctgov
M032-HSV-1synonymcurator

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
F
Replication
conditionally replicating
Modifications
both copies of gamma34.5 deleted; human IL-12 expression cassette inserted
Transgenes
IL12A, IL12B
Route
intratumoral, intracerebral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07076498Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care RadiationRecruitingPhase 12026-04-232029-12-3120Glioma
NCT05084430Study of Pembrolizumab and M032 (NSC 733972)RecruitingPhase 1/22022-02-252027-03-0128Anaplastic Astrocytoma; Glioblastoma Multiforme; Gliosarcoma
NCT02062827Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant GliomaCompletedPhase 12013-11-252022-0929Anaplastic Astrocytoma or Gliosarcoma; Progressive Glioblastoma Multiforme; Recurrent Glioblastoma Multiforme

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 27314913Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.Human gene therapy. Clinical development2016name in title: M032

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 33524948Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.Neurosurgical focus2021name in title: M032
PMID 33005623The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas.Frontiers in surgery2020name in title: M032
PMID 24649838Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.Human gene therapy. Clinical development2014name in title: M032
Unconfirmed matches (5)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 41741902Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors.Journal of neuro-oncology2026name in abstract: M032
PMID 38806994A viral attack on brain tumors: the potential of oncolytic virus therapy.Journal of neurovirology2024name in abstract: M032
PMID 34004331Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.Seminars in cancer biology2022name in abstract: M032
PMID 35342877Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus.Journal of translational genetics and genomics2021name in abstract: M032
PMID 30224769Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.Scientific reports2018name in abstract: M032

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01CA217179A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.UNIVERSITY OF ALABAMA AT BIRMINGHAMMARKERT, JAMES M2017–2019name in title: M032
Unconfirmed matches (4)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

ProjectTitleOrganisationPIYearsLinked by
R33NS128191Development of murine glioblastoma model for oncolytic HSV therapyLSU HEALTH SCIENCES CENTERKAUR, BALVEEN2026–2026name in abstract: M032
R61NS128191Development of murine glioblastoma model for oncolytic HSV therapyAUGUSTA UNIVERSITYKAUR, BALVEEN2024–2025name in abstract: M032
U01CA224151Canine Immuno NeurotherapeuticsUNIVERSITY OF ALABAMA AT BIRMINGHAMCHAMBERS, M R2017–2021name in abstract: M032
P01CA071933Engineered HSV For Treatment of Malignant GliomaUNIVERSITY OF ALABAMA AT BIRMINGHAMWHITLEY, RICHARD J.2009–2013name in abstract: M032

Notes

gamma34.5-deleted oHSV carrying human IL-12 (the murine counterpart is M002). Phase 1 in recurrent glioma (NCT02062827); a further phase 1 in diffuse midline glioma opened in 2025 (NCT07076498). No NCIt concept found for M032.

How to cite

M032 (AXP000086.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000086.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.